Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.

Trial Details

NCT ID
NCT05931393
Phase
PHASE2
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cabozantinib 80 MG
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Patients with advanced RCC (defined as locally advanced unresectable or metastatic) of any histology who progressed on/after cabozantinib monothera…
  • Ability to tolerate prior cabozantinib at 60mg PO daily with manageable toxicity profile at the respective doses, at investigator discretion
  • Prior PD-1 inhibitor/PD-L1 inhibitor allowed
  • Evidence of measurable disease per RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →